Maternal Vaccination in Argentina: Tetanus, Diphtheria, and Acellular Pertussis Vaccine Effectiveness During Pregnancy in Preventing Pertussis in Infants <2 Months of Age.
Tdap
infant pertussis
maternal immunization
pregnancy
vaccine effectiveness
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
16 01 2020
16 01 2020
Historique:
received:
08
10
2018
accepted:
14
03
2019
pubmed:
17
3
2019
medline:
7
1
2021
entrez:
17
3
2019
Statut:
ppublish
Résumé
In 2011, Argentina experienced its highest pertussis incidence and mortality rates of the last decade; 60% of deaths were among infants aged <2 months. In response, a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine was recommended for all pregnant women at ≥20 weeks of gestation. Although recent studies suggest that maternal Tdap vaccination is effective at preventing infant disease, no data have come from low- or middle-income countries, nor from ones using whole-cell pertussis vaccines for primary immunization. We conducted a matched case-control evaluation to assess the effectiveness of maternal Tdap vaccination in preventing pertussis among infants aged <2 months in Argentina. Pertussis case patients identified from September 2012 to March 2016 at 6 hospital sites and confirmed by polymerase chain reaction testing were included. Five randomly selected controls were matched to each case patient by hospital site and mother's health district. We used multivariable conditional logistic regression to calculate odds ratios (ORs). Vaccine effectiveness (VE) was estimated as (1 - OR) × 100%. Seventy-one case patients and 300 controls were included in the analysis. Forty-nine percent of case patients and 78% of controls had mothers who were vaccinated during pregnancy. Overall Tdap VE was estimated at 80.7% (95% confidence interval, 52.1%-92.2%). We found similar VE whether Tdap was administered during the second or third trimester. Tdap vaccination during pregnancy is effective in preventing pertussis in infants aged <2 months in Argentina, with similar effectiveness whether administered during the second or third trimester of pregnancy.
Sections du résumé
BACKGROUND
In 2011, Argentina experienced its highest pertussis incidence and mortality rates of the last decade; 60% of deaths were among infants aged <2 months. In response, a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine was recommended for all pregnant women at ≥20 weeks of gestation. Although recent studies suggest that maternal Tdap vaccination is effective at preventing infant disease, no data have come from low- or middle-income countries, nor from ones using whole-cell pertussis vaccines for primary immunization.
METHODS
We conducted a matched case-control evaluation to assess the effectiveness of maternal Tdap vaccination in preventing pertussis among infants aged <2 months in Argentina. Pertussis case patients identified from September 2012 to March 2016 at 6 hospital sites and confirmed by polymerase chain reaction testing were included. Five randomly selected controls were matched to each case patient by hospital site and mother's health district. We used multivariable conditional logistic regression to calculate odds ratios (ORs). Vaccine effectiveness (VE) was estimated as (1 - OR) × 100%.
RESULTS
Seventy-one case patients and 300 controls were included in the analysis. Forty-nine percent of case patients and 78% of controls had mothers who were vaccinated during pregnancy. Overall Tdap VE was estimated at 80.7% (95% confidence interval, 52.1%-92.2%). We found similar VE whether Tdap was administered during the second or third trimester.
CONCLUSIONS
Tdap vaccination during pregnancy is effective in preventing pertussis in infants aged <2 months in Argentina, with similar effectiveness whether administered during the second or third trimester of pregnancy.
Identifiants
pubmed: 30877308
pii: 5381906
doi: 10.1093/cid/ciz217
pmc: PMC8876368
mid: NIHMS1779039
doi:
Substances chimiques
Diphtheria-Tetanus-acellular Pertussis Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-387Subventions
Organisme : Intramural CDC HHS
ID : CC999999
Pays : United States
Informations de copyright
Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Références
MMWR Recomm Rep. 2018 Apr 27;67(2):1-44
pubmed: 29702631
Pediatrics. 2017 May;139(5):
pubmed: 28557752
JAMA. 2018 Oct 9;320(14):1464-1470
pubmed: 30304426
Vaccine. 2016 Jan 2;34(1):142-50
pubmed: 26592142
Clin Infect Dis. 2019 May 2;68(10):1634-1640
pubmed: 30169627
Clin Infect Dis. 2017 Nov 29;65(12):1977-1983
pubmed: 29028938
Vaccine. 2016 Jun 30;34(31):3613-9
pubmed: 27142328
Arch Argent Pediatr. 2014 Oct;112(5):413-20
pubmed: 25192521
Clin Infect Dis. 2017 Jan 1;64(1):3-8
pubmed: 27624955
Vaccine. 2015 Nov 25;33(47):6413-9
pubmed: 26277071
Clin Infect Dis. 2015 Feb 1;60(3):333-7
pubmed: 25332078
Vaccine. 2018 Mar 7;36(11):1375-1380
pubmed: 29429812
Clin Infect Dis. 2016 Apr 1;62(7):829-836
pubmed: 26797213
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S197-S204
pubmed: 27838673
Vaccine. 2014 Oct 7;32(44):5787-93
pubmed: 25173476
Clin Infect Dis. 2018 Sep 14;67(7):1063-1071
pubmed: 30010773
Vaccine. 2016 Jan 2;34(1):151-9
pubmed: 26529073
JAMA. 2014 May 7;311(17):1760-9
pubmed: 24794369
Clin Infect Dis. 2016 Dec 1;63(suppl 4):S134-S141
pubmed: 27838665
Clin Infect Dis. 2015 Dec 1;61(11):1637-44
pubmed: 26374816
Euro Surveill. 2017 Jun 1;22(22):
pubmed: 28598324
Lancet. 2014 Oct 25;384(9953):1521-8
pubmed: 25037990
Vaccine. 2016 Dec 7;34(50):6223-6228
pubmed: 27847175
Am J Obstet Gynecol. 2016 Aug;215(2):237.e1-6
pubmed: 26968625
Vaccine. 2018 Mar 27;36(14):1887-1892
pubmed: 29501321